Yarrow Bioscience
YARW
34 hedge funds and large institutions have $1.33M invested in Yarrow Bioscience in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 17 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
23% less funds holding
Funds holding: 44 → 34 (-10)
37.64% less ownership
Funds ownership: 53.26% → 15.61% (-38%)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
90% less capital invested
Capital invested by funds: $13.4M → $1.33M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$557K |
| 2 |
SC
Shay Capital
New York
|
+$322K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$277K |
| 4 |
Two Sigma Investments
New York
|
+$144K |
| 5 |
Two Sigma Advisers
New York
|
+$37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.26M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.72M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.06M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.05M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$942K |
YARW Hedge Fund Activity: Q3 2025 in Review
34 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q3 2025, worth a combined $1.33M — down 90% from $13.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of YARW and 7 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $557K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.26M sold.
- 34 institutional investors held Yarrow Bioscience (YARW) as of Q3 2025, down from 44 in Q2 2025.
- Funds reported $1.33M of Yarrow Bioscience stock for Q3 2025, down 90% quarter-over-quarter.
- 7 funds opened new Yarrow Bioscience positions in Q3 2025 and 17 closed out, a net change of -10 holders.
- The largest Yarrow Bioscience buyer in Q3 2025 was Baker Bros. Advisors, an estimated $557K added.
- The largest Yarrow Bioscience seller in Q3 2025 was Cormorant Asset Management, an estimated $2.26M sold.
Based on aggregated 13F filings for Q3 2025.